THOMSON REUTERS
CORTELLIS™

Intercept Pharmaceuticals Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 08-Jul-2013

THOMSON REUTERS
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

TABLE OF CONTENTS

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

Intercept Pharmaceuticals Inc

COMPANY OVERVIEW

Company Name	Intercept Pharmaceuticals Inc
Parent Company Name	Genextra SpA
Website	http://www.interceptpharma.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	1
Number of Patents as Owner	10
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Metabolic disorder,Diabetic nephropathy,Diabetic retinopathy,Diarrhea,Fibrosis,Non-alcoholic steatohepatitis,Portal hypertension,Primary biliary cirrhosis,Inflammatory disease,Autoimmune disease,Cancer,Gastrointestinal disease,Liver disease,Renal disease
Key Target-based Actions	G-protein coupled bile acid receptor 1 agonist,Farnesoid X receptor agonist,G-protein coupled bile acid receptor 1 modulator
Key Technologies	Small molecule therapeutic,Oral formulation,Systemic formulation unspecified

COMPANY PROFILE

SUMMARY

Intercept Pharmaceuticals Inc, headquartered in New York City, NY, is focused on the development of small-molecule drugs for the treatment of chronic liver and metabolic diseases. In May 2006, Genextra acquired Intercept Pharmaceuticals.

FINANCIAL

In June 2013, the company announced an underwritten public offering of 1.73 million shares of its common stock and expects to grant the underwriters a 30-day option to purchase up to an additional 259,500 shares of common stock. Later in June 2013, the company intended to raise net proceeds of approximately $53.3 million from the priced public offering of $33.01 per share. The offering was expected to close on or about June 24, 2013. Later that month, the company raised net proceeds of approximately $61.7 million from the closed offering. At that time, the underwriters fully exercised their option to buy an additional 259,500 common stock shares.

In October 2012, the company announced the pricing of its initial public offering of 5,000,000 shares of common stock, at a price of $15 per share, before underwriting discounts. The underwriters were issued a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept. At that time, the company's shares were expected to begin trading on NASDAQ , on October 11, 2012 under the trading symbol ICPT; later that month, the underwriters purchased the additional shares. The sale of the shares was closed on October 16, 2012.

In September 2012, the company filed a form S-1 registration statement with the US SEC for a proposed IPO of its common stock shares. All the shares would be offered by Intercept, and might not be sold until the registration statement had been effective. At that time, the number of shares and price range for the offering was not determined.

In August 2012, Intercept completed a $30 million series C preferred stock financing.

In January 2010, Intercept raised $25 million from a preferred series B financing by its majority shareholder, Genextra.

In July 2008, the company raised $25 million in equity financing.

In May 2006, Intercept raised $41 million in equity financing.

In May 2005, Intercept completed a $1.3 million convertible debt financing round.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

In August 2004, Intercept completed a $3 million first round financing. It was to use the proceeds to complete its acquisition of INT-747 and related intellectual property and to complete preclinical trials of the drug.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Drugs by Indication Table

Indication	Active	Inactive	Total
Metabolic disorder	1	2	3
Gastrointestinal disease	1	1	2
Inflammatory disease	2	0	2
Cardiovascular disease	2	0	2
Immune disorder	1	0	1
Genitourinary disease	1	0	1
Ocular disease	1	0	1
Endocrine disease	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	2
No Development Reported	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - CRADA	1	0	0	0	1
Drug - Development/Commercialization License	2	0	1	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Gastrointestinal disease	2	6
Immune disorder	2	4
Inflammatory disease	0	2
Metabolic disorder	0	2
Endocrine disease	0	2
Cardiovascular disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	1	5
Phase 1	0	1

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	8	0	8
Endocrine disease	3	0	3
Gastrointestinal disease	10	0	10

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Genitourinary disease	7	0	7
Immune disorder	3	0	3
Neoplasm	3	0	3
Ocular disease	1	0	1
Metabolic disorder	10	0	10
Neurological disease	1	0	1
Nutritional disorder	5	0	5
Inflammatory disease	5	0	5

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

obeticholic acid

obeticholic acid SNAPSHOT

Drug Name	obeticholic acid
Key Synonyms	obeticholic acid
Originator Company	Universita di Perugia
Active Companies	Intercept Pharmaceuticals Inc;Dainippon Sumitomo Pharma Co Ltd
Inactive Companies	Universita di Perugia
Highest Status	Phase 3 Clinical
Active Indications	Liver disease;Primary biliary cirrhosis;Portal hypertension;Diarrhea;Non-alcoholic steatohepatitis
Target-based Actions	Farnesoid X receptor agonist
Other Actions	Antidiarrhoeal;Antihypertensive;Bile acid modulator
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	07-Jun-2013

obeticholic acid DEVELOPMENT PROFILE

SUMMARY

Intercept Pharmaceuticals (a wholly-owned subsidiary of Genextra), under license from the University of Perugia, is developing the farnesoid X receptor (FXR) agonist obeticholic acid (INT-747; UPF-747; 6ECDCA, OCA) for the potential once-daily oral treatment of portal hypertension and liver diseases, such as primary biliary cirrhosis (PBC), bile acid diarrhea and non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) ,. Intercept's Asian licensee Dainippon Sumitomo Pharma is developing the drug (as DSP-1747) for PBC, NASH and other chronic liver diseases. In March 2011, Intercept initiated a phase II/III NASH trial. By October 2012, a phase II trial for NASH was underway in Japan. In March 2011, a phase III PBC trial was expected to initiate in Europe ; in January 2012, a phase III PBC trial began in the US. In December 2012, results from the trial were expected in the second quarter of 2014. In August 2012, the drug was in phase IIa for portal hypertension ; in November 2012, data were reported. In July 2012, a phase IIa trial for bile acid diarrhea was initiated. In May 2013, data were reported.

Previously, the University of Perugia was investigating the compound for the potential treatment of cholestasis. By June 2010, Intercept was also investigating a series of preclinical backup and follow-on FXR compounds, including other bile acid derived and synthetic small molecule compounds, which were being optimized.

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

obeticholic acid DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Intercept Pharmaceuticals Inc	Non-alcoholic steatohepatitis	US	Phase 3 Clinical	03-Mar-2011
Intercept Pharmaceuticals Inc	Primary biliary cirrhosis	US	Phase 3 Clinical	06-Jan-2011
Dainippon Sumitomo Pharma Co Ltd	Non-alcoholic steatohepatitis	Japan	Phase 2 Clinical	31-Oct-2012
Intercept Pharmaceuticals Inc	Diarrhea	UK	Phase 2 Clinical	31-Jul-2012
Intercept Pharmaceuticals Inc	Portal hypertension	Western Europe	Phase 2 Clinical	13-Aug-2012
Dainippon Sumitomo Pharma Co Ltd	Liver disease	China	Discovery	30-Mar-2011
Universita di Perugia	Jaundice	Italy	Discontinued	12-Aug-2004
Universita di Perugia	Liver disease	Italy	Discontinued	12-Aug-2004

obeticholic acid CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
459789-99-2	2



Name	Type
obeticholic acid	INN; USAN
INT-747	Research Code
6ECDCA	

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

obeticholic acid DRUG NAMES

Names	Type
6ECDCA	
OCA, Intercept	
obeticholic acid	INN, USAN
DSP-1747	Research Code
INT-747	Research Code
UPF-747	Research Code
FXR agonists, Intercept	
farnesoid X receptor agonists, Intercept	

obeticholic acid CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Primary biliary cirrhosis											
0	0	1	1	1	2	0	1	0	0	2	4
Non-alcoholic steatohepatitis											
0	0	0	0	2	3	0	1	0	0	2	4
Non-insulin dependent diabetes											
0	0	0	0	0	1	0	1	0	0	0	2
Diarrhea											
0	0	0	0	1	1	0	0	0	0	1	1
Biliary cirrhosis											
0	0	0	0	0	1	0	0	0	0	0	1
Liver disease											
0	0	0	0	0	0	0	1	0	0	0	1
Portal hypertension											
0	0	0	0	0	1	0	0	0	0	0	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	4	8	0	1	0	0	5	10

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

obeticholic acid DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals
Total: 3

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Genextra SpA	2	0	1	0	3
Sumitomo Chemical Co Ltd	0	0	1	0	1
US Government	0	0	1	0	1
Universita di Perugia	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	0	2
Drug - CRADA	1	0	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Genextra SpA	5	0	5
Sumitomo Chemical Co Ltd	4	0	4
Universita di Perugia	1	2	3
City of Hope	1	0	1
Individual	1	0	1
Celldex Therapeutics Inc	1	0	1
GlaxoSmithKline plc	1	0	1
Royal College of Surgeons in Ireland	1	0	1
Erregierre Industria Chimica SpA	1	0	1
US Government	1	0	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	4
Process	2
Product (derivative)	1
Component of Combination	1
Product	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

INT-767

INT-767 SNAPSHOT

Drug Name	INT-767
Key Synonyms	
Originator Company	Intercept Pharmaceuticals Inc
Active Companies	Intercept Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Diabetic nephropathy;Diabetic retinopathy;Fibrosis
Target-based Actions	Farnesoid X receptor agonist;G-protein coupled bile acid receptor 1 agonist
Other Actions	Anti-inflammatory
Technologies	Systemic formulation unspecified;Small molecule therapeutic
Last Change Date	13-Aug-2012

INT-767 DEVELOPMENT PROFILE

SUMMARY

Intercept is investigating INT-767, a dual farnesoid X receptor (FRX) and TGR5 agonist for the potential treatment of fibrosis, diabetic retinopathy and chronic kidney diseases including, diabetic nephropathy ,. In June 2010, the drug was in preclinical development ; in August 2012, this was still the case.

Intercept was previously investigating INT-767, for the potential treatment of metabolic diseases. However, no further development was reported for this indication since August 2012 .

Intercept was also previously investigating FRX and TGR5 bile acid derived back ups. In June 2010, the compounds were under preclinical development. However, no further development was reported since August 2012 .

INT-767 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Intercept Pharmaceuticals Inc	Diabetic nephropathy	US	Discovery	17-Dec-2007
Intercept Pharmaceuticals Inc	Diabetic retinopathy	US	Discovery	22-Jun-2013
Intercept Pharmaceuticals Inc	Fibrosis	US	Discovery	01-Jan-2010
Intercept Pharmaceuticals Inc	Metabolic disorder	US	No Development Reported	13-Aug-2012

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

INT-767 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	4



Name	Type
INT-767	Research Code

INT-767 DRUG NAMES

Names	Type
farnesoid X receptor (FXR)/TGR5 agonist (metabolic disorder/fibrosis), Intercept	
farnesoid X receptor (FXR)/TGR5 agonist (diabetic nephropathy), Intercept	
INT-767	Research Code

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

INT-777

INT-777 SNAPSHOT

Drug Name	INT-777
Key Synonyms	
Originator Company	Intercept Pharmaceuticals Inc
Active Companies	Intercept Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Metabolic disorder
Target-based Actions	G-protein coupled bile acid receptor 1 agonist
Other Actions	
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	30-Nov-2012

INT-777 DEVELOPMENT PROFILE

SUMMARY

Intercept Pharmaceuticals is investigating INT-777, a modified bile acid and TGR5 agonist, for the potential oral treatment of metabolic disorders including diabetes and obesity,. By December 2007, the drug was in preclinical development; in August 2012, this was still the case.

By June 2010, Intercept was also characterizing additional series of backup TGR5 agonists, including other bile acid derived and synthetic small molecule compounds.

INT-777 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Intercept Pharmaceuticals Inc	Metabolic disorder	US	Discovery	17-Dec-2007

INT-777 CHEMICAL STRUCTURES

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

CAS Registry Number:	Confidence Level:
	3



Name	Type
INT-777	Research Code

INT-777 DRUG NAMES

Names	Type
TGR5 agonist (oral, metabolic disorder), Intercept	
INT-777	Research Code

INT-777 DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart



Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Genextra SpA	2	0	2

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	2
New use	1

Return to Table of Contents

© 2013 Thomson Reuters All rights reserved

THOMSON REUTERS

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

Return to Table of Contents